Literature DB >> 8794495

The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse.

B Kirkpatrick1, X F Amador, M Flaum, S A Yale, J M Gorman, W T Carpenter, M Tohen, T McGlashan.   

Abstract

Drug abuse is common in schizophrenia. Previous studies suggested patients with the deficit syndrome have a lower risk of drug abuse than do patients without deficit features. We distinguished deficit and nondeficit groups in the DSM-IV Field Trial dataset, and compared the two groups relative to current and lifetime (worst ever) severity of alcohol, cannabis, and other drugs of abuse. Deficit syndrome patients had a lower severity of current use of alcohol and other drugs, but the two groups did not differ significantly relative to cannabis use. Deficit patients also had less severe lifetime use of all three classes of drugs. These findings could not be attributed to differences between the deficit and nondeficit groups in demographics, severity of psychotic symptoms, chronicity of illness, or the quality of information available for the two groups. Deficit categorization and drug abuse were independently associated with poor level of function. Negative symptoms broadly defined were weaker predictors of drug abuse than was the deficit/nondeficit categorization. These findings further support the validity of the deficit syndrome of schizophrenia. Within schizophrenia, groups with relatively high or low risk for substance abuse can be identified.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794495     DOI: 10.1016/0920-9964(95)00102-6

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  24 in total

1.  Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features.

Authors:  Clemente Garcia-Rizo; Emilio Fernandez-Egea; Cristina Oliveira; Azucena Justicia; Miguel Bernardo; Brian Kirkpatrick
Journal:  Psychiatry Res       Date:  2012-03-08       Impact factor: 3.222

2.  The brief negative symptom scale: psychometric properties.

Authors:  Brian Kirkpatrick; Gregory P Strauss; Linh Nguyen; Bernard A Fischer; David G Daniel; Angel Cienfuegos; Stephen R Marder
Journal:  Schizophr Bull       Date:  2010-06-17       Impact factor: 9.306

Review 3.  Revisiting the diagnosis of schizophrenia: where have we been and where are we going?

Authors:  William R Keller; Bernard A Fischer; William T Carpenter
Journal:  CNS Neurosci Ther       Date:  2010-12-27       Impact factor: 5.243

4.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

Review 5.  Substance abuse and schizophrenia: pharmacotherapeutic intervention.

Authors:  Alan I Green; Douglas L Noordsy; Mary F Brunette; Christopher O'Keefe
Journal:  J Subst Abuse Treat       Date:  2007-06-15

6.  Differences in glucose tolerance between deficit and nondeficit schizophrenia.

Authors:  Brian Kirkpatrick; Emilio Fernandez-Egea; Clemente Garcia-Rizo; Miguel Bernardo
Journal:  Schizophr Res       Date:  2008-11-28       Impact factor: 4.939

7.  Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.

Authors:  Amber L Bahorik; Christina E Newhill; Shaun M Eack
Journal:  Schizophr Bull       Date:  2013-07-24       Impact factor: 9.306

Review 8.  The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases.

Authors:  Jenny Lam; Nichole Coleman; April Lourdes A Garing; Heike Wulff
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

9.  Will the Kraepelinian dichotomy survive DSM-V?

Authors:  Bernard A Fischer; William T Carpenter
Journal:  Neuropsychopharmacology       Date:  2009-03-18       Impact factor: 7.853

10.  White matter alterations in deficit schizophrenia.

Authors:  Laura M Rowland; Elena A Spieker; Alan Francis; Peter B Barker; William T Carpenter; Robert W Buchanan
Journal:  Neuropsychopharmacology       Date:  2008-12-03       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.